Regulation of airway eosinophil and neutrophil infiltration by α-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease

Vaccine

Volumn 25, Issue 45, 2007, Pages 7754-7762

  Benoit, Anita C ^a   Huang, Yan ^a   Maneewatchararangsri, Santi ^a,b   Tapchaisri, Pramuan ^b   Anderson, Robert ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Galactosylceramide in liposome vaccine; Respiratory syncytial virus (RSV) G protein vaccine; Respiratory syncytial virus (RSV) associated inflammation; Vaccine augmented respiratory syncytial virus (RSV) disease

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; ALPHA GALACTOSYLPHOSHATIDYLGLYCEROYLALKYLAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 13; LIPID; LIPOSOME; MESSENGER RNA; RECOMBINANT PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; LUNG LAVAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY TRACT DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; EOSINOPHILS; GALACTOSYLCERAMIDES; INTERLEUKIN-3; LIPOSOMES; LUNG; LUNG DISEASES; MICE; MICE, INBRED BALB C; NEUTROPHIL INFILTRATION; NEUTROPHILS; PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 35348921095     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.062     Document Type: Article

References (38)

1. Alving C.R. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann NY Acad Sci 31 (1995) 143-152
2. Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., and Alving C.R. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect Immun 66 (1998) 2859-2865
3. Ryan E.J., Daly L.M., and Mills K.H. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 19 (2001) 293-304
4. Spickler A.R., and Roth J.A. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 17 (2003) 273-281
5. Kobayashi E., Motoki K., Uchida T., Fukushima H., and Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7 (1995) 529-534
6. Morita M., Motoki K., Akimoto K., Natori T., Sakai T., Sawa E., et al. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 38 (1995) 2176-2187
7. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278 (1997) 1626-1629
8. Burdin N., Brossay L., and Kronenberg M. Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 29 (1999) 2014-2025
9. Singh N., Hong S., Scherer D.C., Serizawa I., Burdin N., Kronenberg M., et al. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 163 (1999) 2373-2377
10. Hong S., Scherer D.C., Singh N., Mendiratta S.K., Serizawa I., Koezuka Y., et al. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev 169 (1999) 31-44
11. Kakimi K., Guidotti L.G., Koezuka Y., and Chisari F.V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192 (2000) 921-930
12. van Dommelen S.L., Tabarias H.A., Smyth M.J., and Degli-Esposti M.A. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol 77 (2003) 1877-1884
13. Johnson T.R., Hong S., Van Kaer L., Koezuka Y., and Graham B.S. NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 76 (2002) 4294-4303
14. Mader D., Huang Y., Wang C., Fraser R., Issekutz A.C., Stadnyk A.W., et al. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge. Vaccine 18 (2000) 1110-1117
15. Huang Y., and Anderson R. Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids from Deinococcus radiodurans. Vaccine 20 (2002) 1586-1592
16. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C., and Murphy B.R. Enhanced pulmonary histopathology induced by Respiratory Syncytial Virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of Interleukin-4 (IL-4) and IL-10. J Virol 68 (1994) 5321-5325
17. Anderson R., and Hansen K. Structure of a novel phosphoglycolipid from Deinococcus radiodurans. J Biol Chem 260 (1985) 12219-12223
18. Baron J.L., Gardiner L., Nishimura S., Shinkai K., Locksley R., and Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 16 (2002) 583-594
19. Exley M.A., Bigley N.J., Cheng O., Tahir S.M., Smiley S.T., Carter Q.L., et al. CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J Leuk Biol 69 (2001) 713-718
20. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195 (2002) 617-624
21. Nieuwenhuis E.E., Matsumoto T., Exley M., Schleipman R.A., Glickman J., Bailey D.T., et al. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 8 (2002) 588-593
22. Cannon M.J., Openshaw P.J.M., and Askonas B.A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 163 (1988) 1163-1168
23. Bendelac A., Rivera M.N., Park S.H., and Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity, and function. Ann Rev Immunol 15 (1997) 535-562
24. Kawamura T., Takeda K., Mendiratta S.K., Kawamura H., Van Kaer L., Yagita H., et al. Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 160 (1998) 16-19
25. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., and Baxter A.G. NKT cells: facts, functions and fallacies. Immunol Today 21 (2000) 573-583
26. Joyce S. Natural T cells: cranking up the immune system by prompt cytokine secretion. Proc Natl Acad Sci USA 97 (2000) 6933-6935
27. Morishima Y., Ishii Y., Kimura T., Shibuya A., Shibuya K., Hegab A.E., et al. Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide. Eur J Immunol 35 (2005) 2803-2814
28. Matthews S.P., Tregoning J.S., Coyle A.J., Hussell T., and Openshaw P.J. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol 79 (2005) 2050-2057
29. Johnson T.R., and Graham B.S. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73 (1999) 8485-8495
30. Johnson T.R., Parker R.A., Johnson J.E., and Graham B.S. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 170 (2003) 2037-2045
31. Huang Y., and Anderson R. Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus. J Virol 79 (2005) 4527-4532
32. Zhou W., Hashimoto K., Moore M.L., Elias J.A., Zhu Z., Durbin J., et al. IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes Infect 8 (2006) 2880-2889
33. Hornsleth A., Loland L., and Larsen L.B. Cytokines and chemokines in respiratory secretion and severity of disease in infants with respiratory syncytial virus (RSV) infection. J Clin Virol 21 (2001) 163-170
34. Noah T.L., Ivins S.S., Murphy P., Kazachkova I., Moats-Staats B., and Henderson F.W. Chemokines and inflammation in the nasal passages of infants with respiratory syncytial virus bronchiolitis. Clin Immunol 104 (2002) 86-95
35. Haeberle H.A., Kuziel W.A., Dieterich H.J., Casola A., Gatalica Z., and Garofalo R.P. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology. J Virol 75 (2001) 878-890
36. Miller A.L., Bowlin T.L., and Lukacs N.W. Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 189 (2004) 1419-1430
37. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., et al. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786-1789
38. Speak A.O., Salio M., Neville D.C., Fontaine J., Priestman D.A., Platt N., et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc Natl Acad Sci USA 104 (2007) 5971-5976